Phase I/II Study of Spartalizumab (PDR001), An Anti-PD1 Mab, in Patients with Advanced Melanoma or Non-Small Cell Lung Cancer

No Thumbnail Available

Date

2018

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

Citation

URI

http://hdl.handle.net/11727/8821

Collections

Tıp Fakültesi / Faculty of Medicine

Endorsement

Review

Supplemented By

Referenced By